• $8M revenue in FY25, +86% YoY growth, and nearly 5X growth in two years
• On track for breakeven in 2026
• Pioneering the global kava industry

The Calmer Co International Limited (ASX:CCO) is a fast-growing CPG company leveraging a global opportunity in kava, a clinically proven alternative to alcohol and pharmaceuticals that supports relaxation and sleep. The company reported strong financial results in FY25, with revenue reaching $8 million, representing an impressive 86% year-over-year growth and nearly a fivefold increase in just two years. This growth was driven by strong performance across all sales channels, including e-commerce, retail, and wholesale. The retail channel, in particular, saw a 68% increase in sales, driven by expanded listings with major Australian retailers Coles and Woolworths, which enhanced brand awareness and highlighted widespread consumer acceptance in Western markets. The company's USA-based sales also grew by 21% in the quarter, fueled by the launch of new products such as flavored kava shots and strong demand for its wholesale offerings, including Kavaton and high-concentration CO2 extracts. The Calmer Co has invested 15 years in developing a vertically integrated supply chain that is difficult to replicate, and it is well-positioned to capitalize on the growing global kava trend. With the company on track for breakeven in 2026, The Calmer Co is pioneering the global kava industry and delivering impressive growth.

The Calmer Co reported $8 million in revenue for FY25, representing an 86% year-over-year growth, and is on track for breakeven in 2026.

The Calmer Co is well-positioned to capitalize on the growing global kava trend, with strong performance across all sales channels and the launch of new products driving growth in the USA market. The company's vertically integrated supply chain and innovative wholesale product formats put it in a strong position to maintain its leadership in the rapidly expanding kava industry.